GlassScriptPhysician profile
Jaime E Ruiz Montero
NPI 1245360726
$9,920.04
in general payments reported to CMS, 2019-2025
34 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,090 · 2020: $1,811 · 2021: $1,115 · 2022: $899 · 2023: $1,244 · 2024: $1,601 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,963.39 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,378.04 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $896.09 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $582.78 | 2019-2023 | |
| Abbvie INC. | $555.02 | 2019-2023 | Vraylar, Ubrelvy, Synthroid |
| Lilly USA, LLC | $520.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $439.24 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $436.89 | 2021-2025 | |
| Pfizer INC. | $329.24 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.78 | 2019-2025 | Tradjenta, Jardiance, Trijardy Xr |
| Merck Sharp & Dohme LLC | $322.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $294.79 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $232.74 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.71 | 2019-2022 | |
| Exact Sciences Corporation | $183.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $161.36 | 2019-2020 | |
| Lundbeck LLC | $127.88 | 2023-2024 | Rexulti |
| Vifor Pharma, INC. | $127.14 | 2019-2020 | |
| Esperion Therapeutics, INC. | $119.91 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $115.24 | 2023-2025 | Rexulti |
| Intuitive Surgical, INC. | $112.23 | 2025 | |
| Xeris Pharmaceuticals, INC. | $61.75 | 2022-2023 | Gvoke Hypopen |
| Abbott Laboratories | $60.10 | 2023-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $51.14 | 2019-2022 | |
| Almatica Pharma LLC | $48.87 | 2023-2025 | Loreev Xr, Gralise |
| Ibsa Pharma INC. | $42.45 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $40.45 | 2019-2022 | |
| Glaxosmithkline, LLC. | $34.96 | 2022-2023 | Arexvy, Shingrix |
| Amneal Pharmaceuticals LLC | $32.66 | 2021-2024 | Unithroid |
| Azurity Pharmaceuticals, INC. | $31.80 | 2023 | Edarbi |
| Takeda Pharmaceuticals U.S.A., INC. | $28.80 | 2019 | |
| Ironwood Pharmaceuticals, INC | $23.00 | 2019 | |
| Dexcom, INC. | $14.80 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Ruiz Montero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.